Re transduced with a pooled library (90k library) of 91,320 gRNAs in lentiviral vectors targeting 17,232 genes at a ratio of 6 gRNAs per gene (14). These cells have been transduced at a multiplicity of infection (MOI) of approximately 0.3.four to obtain coverage of at the least 200-fold per gRNA. One day posttransduction, cells had been treated with puromycin (two g/mL) for 48 hours to choose transduced cells. Cells had been then treated with DMSO or TAK-243 at its IC90 (25 nM) or IC99 (30 nM) for 32 days. Genomic DNA was then extracted from cellJCI insight 2021;6(five):e141518 https://doi.org/10.1172/jci.insight.141518RESEARCH ARTICLEpopulations; gRNA sequences have been amplified by PCR and sequenced on an Illumina Hiseq2500. Data have been analyzed using MAGeCK method (15). CRISPR/Cas9 knockout and shRNA-mediated knockdown experiments. For CRISPR/Cas9 knockout experiments, OCI-AML2-Cas9 cells (5 106) were resuspended in five mL of fresh media containing protamine sulfate (five g/mL). Viral supernatants (2 mL) of 2 distinct BEND3-targeting gRNAs encoded in pLCKO lentiviral vectors (gBEND3 #1 and #2) were added to cells to attain an MOI of 0.3 (Addgene plasmid 73311; ref. 14). Just after 24 hours of incubation, cells were centrifuged at 600g for five minutes at 25 and resuspended in fresh media containing puromycin (1.five g/mL). Right after three days of selection, cell lysates have been collected, and knockout was then confirmed by immunoblotting. BEND3 was also knocked out working with a single-plasmid technique encoding more gRNAs. To perform so, OCI-AML2 cells had been transduced with lentiCRISPR v2 vectors encoding Cas9 and 3 distinct BEND3-targeting gRNAs (crV2-BEND3 #1-3) as described above (Addgene plasmid 52961; ref. 56). For shRNA-mediated knockdown experiments, ABCG2-targeting shRNAs had been obtained from MilliporeSigma (product SHCLNG-NM_004827) and transduced into A549 and RPMI 8226 cells as described above. Sequences of BEND3-targeting gRNAs and ABCG2-targeting shRNAs are listed in Supplemental Table four. Cytotoxicity assays. CellTiter 96 AQueous MTS Reagent Powder was purchased from Promega (catalog G1111) and annexin NMDA Receptor drug V-FITC apoptosis kit from Biovision (catalog K101-400). The MTS and annexin V/PI Transthyretin (TTR) Inhibitor drug assays have been performed as per the manufacturer’s guidelines. For the MTS assay, the cells have been counted and seeded in 96-well plates in the following densities: OCI-AML2 (25,000/well), K562 (10,000/well), MV4-11 (25,000/well), RPMI 8226 (25,000/well), NB4 (25,000/well), U937 (ten,000/ nicely), MDAY-D2 (10,000/well), and Jurkat (ten,000/well) and treated with escalating concentrations of the drug(s) beneath investigation. Immediately after 72 hours of incubation, the MTS solution was directly added for the media at a ratio of 1:five, and absorbance was measured at 490 nm employing SpectraMax Microplate Reader (Molecular Devices). The growth and viability have been then calculated as a percentage in the untreated cells, and concentration-response curves had been constructed and IC50 calculated applying the nonlinear regression function in GraphPad Prism (Version 6.03, GraphPad Application Inc.). For the annexin V/PI assay, OCI-AML2 cells had been seeded inside a 24-well plate at a plating density of 1 105 cells/mL and treated with increasing concentrations of TAK-243. Just after 96 hours of incubation, media have been collected, and cells have been washed with phosphate-buffered saline (PBS), centrifuged at 900g at 25 for 10 minutes, and then resuspended within the binding buffer containing annexin V-FITC and PI. Unstained and single-stained cells have been employed as compensation co.
